Senators Amy Klobuchar (D-MN) and Jeanne Shaheen (D-NH) have sent a letter to the FDA urging the regulatory body to find efficient ways to distribute expensive cancer drugs.
A study published by researchers at the Memorial Sloan Kettering Cancer Center (MSKCC) and the University of Chicago urging the pharmaceutical industry to rethink its approach to packaging cancer drugs into a one-size vial to avoid drug wastage has set some political wheels in motion. Senators Amy Klobuchar (D-MN) and Jeanne Shaheen (D-NH) have sent a letter to newly elected FDA commissioner Robert Califf, MD, urging the regulatory body to find efficient ways to distribute these drugs.
Both senators have been very active with addressing the cost of prescription medications. Shaheen is a cosponsor of the Medicare Prescription Drug Price Negotiation Act, which would empower Medicare—on behalf of seniors enrolled in the program—to negotiate pricing for drugs covered under Medicare Part D, similar to commercial health plans.
In their letter addressed to Califf, the lawmakers wrote, “Cancer takes an emotional, physical and financial toll on patients and families. The current practice encourages waste and drives up costs for patients who rely on these lifesaving medications. Because the drugs used to treat cancer are expensive, even small amounts of leftover medication can be extremely costly for patients and the health system. Families fighting cancer should not have to worry about being able to afford the next dose of medication. We urge the FDA to examine this practice to see if there is a more efficient way to deliver this crucial medication to the patients that need it.”
A more efficient packaging of expensive specialty medications such as anticancer drugs is just one piece that can help solve the cost puzzle faced by our healthcare system. But it does lead us to think that out-of-the-box solutions that might necessitate foundational changes, might be an answer.
In an interview with Morning Consult, Peter Bach, MD, the author of the above BMJ study from MSKCC, said, “Pharmaceutical companies aren’t evil. They’re for-profit companies in a system that’s been designed for them. They’re doing what they should do.” According to Bach, indication-specific pricing and quality-of-care—based reimbursement—policy moves that are actively being pursued by the healthcare industry—are just some of the undertakings that can help see the change.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More